Healthcare / BiotechnologyKOSDAQ
$57500.00
-2500.00 (-4.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.6B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.33T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.1%
↓Gross Margin
100.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-44.8%
FCF CAGR
—
FCF margin
-167.1%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.17B · net income $-9.73B · FCF $-3.63B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.17B | $2.17B | $27.51B | — | $200.0M | $23.40B |
| Net Income | $-9.73B | $-9.73B | $20.01B | $-14.13B | $-8.96B | — |
| EBITDA | $-8.42B | $-8.42B | $22.13B | $-12.52B | $-8.34B | — |
| EPS | -429.00 | -429.00 | 913.00 | -662.00 | -229.00 | — |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% |
| Operating Margin | -334.4% | -334.4% | 61.3% | — | -5737.2% | — |
| Net Margin | -447.9% | -447.9% | 72.7% | — | -4479.6% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.10 | 0.00 | — |
| Current Ratio | 110.34 | 110.34 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-3.63B | $-3.63B | $21.51B | $-10.57B | $-6.79B | — |
| Returns | ||||||
| ROE | -10.1% | -10.1% | 22.0% | -24.5% | -13.0% | — |
| Valuation | ||||||
| P/E | — | — | 18.29 | — | — | — |
| EV/EBITDA | — | — | 16.52 | — | — | — |
| P/B | 13.54 | 13.54 | 4.02 | 5.38 | 2.33 | — |
| Growth & Yield | ||||||
| Revenue Growth | -92.1% | -92.1% | — | — | -99.1% | — |
| EPS Growth | -147.0% | -147.0% | 237.9% | -189.1% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+238.2%
Start / end P/E
n/dx → n/dx
EPS bridge
913.00 → -429.00
Residual
+238.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.